{"id":3417,"date":"2026-05-11T11:00:00","date_gmt":"2026-05-11T09:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7cfdd15124fb0aad04c90dc431c63a20"},"modified":"2026-05-11T11:00:00","modified_gmt":"2026-05-11T09:00:00","slug":"abl-diagnostics-reports-historic-2025-annual-results-net-income-explosion-246-strong-operating-profitability-and-global-acceleration","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=3417","title":{"rendered":"ABL Diagnostics Reports Historic 2025 Annual Results: Net Income Explosion (+246%), Strong Operating Profitability and Global Acceleration"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li class=\"bwalignc\">\n<i>Strong revenue growth of +30.4% to \u20ac6.95m<\/i><\/li>\n<li class=\"bwalignc\">\n<i>Positive operating income of \u20ac290k, exceeding analyst forecasts<\/i><\/li>\n<li class=\"bwalignc\">\n<i>Net income soaring to nearly \u20ac1m (\u20ac987k)<\/i><\/li>\n<li class=\"bwalignc\">\n<i>International business acceleration: 70% of revenue generated outside France, with a network expanded to 57 distributors across 50 countries<\/i><\/li>\n<li class=\"bwalignc\">\n<i>A year of major transformation with the integration of Fast Track Diagnostics (FTD) syndromic PCR tests, the Vela Diagnostics range, and the Institut Pasteur HPV RNA-Seq test<\/i><\/li>\n<\/ul><p>WOIPPY, France--(BUSINESS WIRE)--Regulatory News:<\/p><p>\nABL Diagnostics (Paris:ABLD)(Euronext Compartment B \u2013 ISIN: FR001400AHX6), a company specialized in in vitro diagnostics, today announces its annual results for the fiscal year ended December 31, 2025, approved by the Board of Directors during its meeting on April 30, 2026.<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwrowaltcolor1 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Financial Indicator<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>FY 2025<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>FY 2024<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Change (%)<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Revenue<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac6,950k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac5,330k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+30.4%<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Operating Result<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac290k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-\u20ac490k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+159.2%<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Net Income<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac987k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac285k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+246.0%<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Cash-Flow from Operations<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac1,383k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac622k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+142.5%<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Cash on Hand (gross)<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac1,316k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac529k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+148.8%<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth50\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Net Debt<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac933k<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u20ac2,024k<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-53.9%<\/p><\/td><\/tr>\n<\/table><p>\n<b>Profitability exceeding market expectations<\/b><\/p><p>\nFiscal year 2025 marks a key milestone in ABL Diagnostics' financial performance. By prioritizing a controlled and qualitative deployment of its new ranges, the Company generated solid revenue of \u20ac6.95m, up +30.4% compared to 2024.<\/p><p>\nIn terms of profitability, the Company is showing robust momentum. Thanks to rigorous cost management and the recurrence of its historical activities, ABL Diagnostics recorded an operating result of \u20ac290k, exceeding the \u20ac190k initially anticipated by AllInvest equity research<sup>1<\/sup>.<\/p><p>\nThis operational control allowed net income to reach \u20ac987k (compared to \u20ac285k in 2024), representing a +246% increase. Cash flow from operations more than doubled to reach \u20ac1.38m, bringing cash on hand to \u20ac1.31m while reducing net debt by more than half (\u20ac933k vs. \u20ac2.02m at end-2024).<\/p><p>\n<b>Expansion of global footprint and product portfolio<\/b><\/p><p>\nThe year 2025 confirms ABL Diagnostics' ability to deploy its model on a global scale. Internationalization has increased, with 70% of revenue now generated outside France (vs. 66% in 2024). This trend is particularly visible in the \"Grand Export\" zone (including Japan and India), which now represents 30% of global revenue, as well as in the United States (4% vs. 1%).<\/p><p>\nTo support this growth, ABL Diagnostics now relies on 57 active distributors covering 50 countries (vs. 44 distributors in 39 countries in 2024). At the same time, the catalog has been significantly enriched, growing from 100 to 147 active product references, illustrating the Company's innovation and integration momentum.<\/p><p>\nBeyond financial aggregates, the fiscal year was marked by the completion of major partnerships:<\/p><ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Acquisition of Fast Track Diagnostics (FTD) assets:<\/span> ABL Diagnostics successfully integrated the development and commercialization of a wide range of syndromic PCR tests (simultaneous detection of multiple pathogens), strengthening its molecular diagnostic offering.<\/li>\n<li>\n<span class=\"bwuline\">Innovation with Institut Pasteur:<\/span> Exclusive global license agreement for the industrialization of the next-generation HPV RNA-Seq test.<\/li>\n<li>\n<span class=\"bwuline\">Alliance with Vela Diagnostics:<\/span> Exclusive distribution agreement for the EMEA zone.<\/li>\n<li>\n<span class=\"bwuline\">Synergies with CDL Pharma:<\/span> Global distribution of CDL Pharma's Clinical Research Organization (CRO) services.<\/li>\n<\/ul><p>\n<b>Outlook<\/b><\/p><p>\nWith an expanded scope, ABL Diagnostics approaches 2026 with confidence, focused on accelerating its new growth drivers and maintaining financial discipline.<\/p><p>\n<b>About ABL Diagnostics (ABLD)<\/b><\/p><p>\nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p><ul class=\"bwlistdisc\">\n<li>\nMolecular polymerase chain reaction (PCR) detection \u2013 UltraGene, and<\/li>\n<li>\nGenotyping by DNA sequencing \u2013 DeepChek\u00ae.<\/li>\n<\/ul><p>\nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p><p>\nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p><p>\n<b>An expanding portfolio of microbiology products:<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nHIV \u2013 Drug resistance testing, including a whole genome kit.<\/li>\n<li>\nSARS-CoV-2, Tuberculosis, Hepatitis B and C \u2013 Advanced Detection Solutions.<\/li>\n<li>\nMicrobiome and taxonomy \u2013 16s\/18s RNA-based analyses.<\/li>\n<li>\nOther viral and bacterial targets \u2013 Comprehensive molecular assays.<\/li>\n<\/ul><p>\n<b>Integrated Solutions<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nReal-time syndromic PCR tests<\/li>\n<li>\nNadis\u00ae \u2013 Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.<\/li>\n<li>\nMediaChek\u00ae \u2013 Clinical Sample Collection Kits.<\/li>\n<\/ul><p>\nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">_______________________________<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<sup>1<\/sup> The study can be viewed at: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abldiagnostics.com%2Fwp-content%2Fuploads%2F2026%2F01%2FFlash-ABL-Diagnostics-22012026_EDITED.pdf&amp;esheet=54533161&amp;newsitemid=20260510972191&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.abldiagnostics.com%2Fwp-content%2Fuploads%2F2026%2F01%2FFlash-ABL-Diagnostics-22012026_EDITED.pdf&amp;index=1&amp;md5=3dfaef9a6a994d1d682c5a7829c52307\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.abldiagnostics.com\/wp-content\/uploads\/2026\/01\/Flash-ABL-Diagnostics-22012026_EDITED.pdf<\/a><\/p><\/td><\/tr>\n<\/table><p>\n\u00a0<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>ABL Diagnostics SA<\/b><br\/>Soci\u00e9t\u00e9 anonyme au capital de 1 611 465,60 euros\n<br\/>Headquarters: 72C route de Thionville - 57140 WOIPPY\n<br\/>552 064 933 R.C.S. METZ<\/p><p>\nTel : +33 (0)7 83 64 68 50\n<br\/>Email: <a  href=\"mailto:info@abldiagnostics.com\" rel=\"nofollow\" shape=\"rect\">info@abldiagnostics.com<b><\/b><\/a><br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;esheet=54533161&amp;newsitemid=20260510972191&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&amp;index=2&amp;md5=6376d458c0ceb9ac0ceb3fc702ca002e\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.abldiagnostics.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Strong revenue growth of +30.4% to \u20ac6.95m<\/p>\n<p>Positive operating income of \u20ac290k, exceeding analyst forecasts<\/p>\n<p>Net income soaring to nearly \u20ac1m (\u20ac987k)<\/p>\n<p>International business acceleration: 70% of revenue generated outside France, with a network expande&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3417","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3417"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3417\/revisions"}],"predecessor-version":[{"id":3418,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3417\/revisions\/3418"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}